May 25, 2016 / 12:22 AM / in a year

BRIEF-Resverlogix explores potential of Apabetalone in phase 3 Betonmace clinical study

May 24 (Reuters) - Resverlogix Corp

* Potential of Apabetalone for treatment of high-risk diabetes and CKD is being explored in co’s phase 3 Betonmace clinical study

* Says no increase in infections was reported in phase 2 trials

Source text for Eikon:

Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below